Bilaga W1404-2.2.pdf - LIF

lif.se

Bilaga W1404-2.2.pdf - LIF

Uttalad inflammationToradol 30 mg/mL.Ge 0,5 mL bolus iv, kan upprepas en gång efter 30 minuter.Dynastat vid blödningsrisk 40 mg iv.Vid svikt av konventionell terapiKetalar 10, 50 mg/mL.Ge 5 mg bolus, kan upprepas, psykotropa biverkningarbegränsar.Referenser1. Haugen DF, Hjermstad MJ, et al. Assessment and classification of cancerbreakthrough pain: A systematic literature review. Pain 2010.2. Lundstrom S, Gyllenhammar E, et al. Together we can: experiencesfrom 7 years of cross-sectional studies in a Swedish palliative careclinical research network. Palliat Med 2010;24(3):261–6.3. Kujath K, Hermann KG, et al. Severe disease activity and complicationsof immunosuppressive therapy: a challenge for acute hospital-based rehabilitationin rheumatology. J Rheumatol 2009;36(8):1618–25.4. Casserly IP. Interventional management of critical limb ischemia inrenal patients. Adv Chronic Kidney Dis 2008;15(4):384–95.5. Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesicdrug development. Anesthesiology 2001;95(1):241–9.6. Davis MP, Walsh D, et al. Controversies in pharmacotherapy of painmanagement. Lancet Oncol 2005;6(9):696–704.7. Bannwarth B. Irrelevance of the WHO analgesic ladder for managingrheumatic pain. Joint Bone Spine 2010;77(1):1–3.8. Strang P. Cancerrelaterad smärta, 2003.9. Geber C, Baumgartner U, et al. Revised definition of neuropathic painand its grading system: an open case series illustrating its use in clinicalpractice. Am J Med 2009;122(Suppl 10):3–12.10. Moryl N, Coyle N, et al. Managing an acute pain crisis in a patient withadvanced cancer: this is as much of a crisis as a code. JAMA 2008;299(12):1457–67.11. Duggan ST, Scott LJ. Intravenous paracetamol (acetaminophen).Drugs 2009;69(1):101–13.12. Tasmacioglu B, Aydinli I, et al. Effect of intravenous administration ofparacetamol on morphine consumption in cancer pain control. SupportCare Cancer 2009;17(12):1475–81.13. Israel FJ, Parker G, et al. Lack of benefit from paracetamol (acetaminophen)for palliative cancer patients requiring high-dose strong opioids:a randomized, double-blind, placebo-controlled, crossover trial. JPain Symptom Manage 2010;39(3):548–54.14. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors,and lessons from the clinic. FASEB J 2004;18(7):790–80415. Antman EM, Bennett JS, et al. Use of nonsteroidal antiinflammatorydrugs: an update for clinicians: a scientific statement from the AmericanHeart Association. Circulation 2007;115(12):1634–42.16. Zemmel MH. The role of COX-2 inhibitors in the perioperative setting:efficacy and safety--a systematic review.” AANA J 2006;74(1):49–60.17. Lloyd R, Derry S, et al. Intravenous or intramuscular parecoxib foracute postoperative pain in adults. Cochrane Database Syst Rev2009;(2):CD004771.18. Sinha VR, Kumar RV, et al. Ketorolac tromethamine formulations: anoverview. Expert Opin Drug Deliv 2009;6(9):961–75.19. Legge J, Ball N, et al. The potential role of ketamine in hospice analgesia:a literature review. Consult Pharm 2006;21(1):51–7.20. Stefanczyk-Sapieha L, Oneschuk D, et al. Intravenous ketamine ”burst”for refractory depression in a patient with advanced cancer. J PalliatMed 2008;11(9):1268–71.21. Hudetz JA, Patterson KM, et al. Ketamine attenuates delirium aftercardiac surgery with cardiopulmonary bypass. J Cardiothorac VascAnesth 2009;23(5):651–7.22. Mercadante S, Villari P, et al. Pamidronate in incident pain due to bonemetastases. J Pain Symptom Manage 2001;22(2):630–1.23. Persson J. The ketamine enigma. Acta Anaesthesiol Scand2008;52(4):453–5.24. Okon T. Ketamine: an introduction for the pain and palliative medicinephysician. Pain Physician 2007;10(3):493–500.25. Miller KE, Miller MM, et al. Challenges in pain management at the endof life. Am Fam Physician 2001;64(7):1227–34.26. Mercadante S, Villari P, et al. Opioid switching and burst ketamine toimprove the opioid response in patients with movement-related paindue to bone metastases. Clin J Pain 2009;25(7):648–9.27. Jensen TS, Finnerup NB. Neuropathic pain treatment: a further stepforward. Lancet 2009;374(9697):1218–9.28. Attal N. Management of neuropathic cancer pain. Ann Oncol2010;21(5):1134–5.29. Sharma S, Rajagopal MR, et al. A phase II pilot study to evaluate use ofintravenous lidocaine for opioid-refractory pain in cancer patients. JPain Symptom Manage 2009;37(1):85–93.30. Buchanan DD, JMF. A role for intravenous lidocaine in severe cancerrelatedneuropathic pain at the end-of-life. Support Care Cancer,2010.31. Bartusch SL, Sanders BJ, et al. Clonazepam for the treatment of lancinatingphantom limb pain. Clin J Pain 1996;12(1):59–62.32. Giovannoni MP, Ghelardini C, et al. Alpha2-agonists as analgesicagents. Med Res Rev 2009;29(2):339–68.33. Myers J, Chan V, et al. Intraspinal techniques for pain management incancer patients: a systematic review. Support Care Cancer2010;18(2):137–49.34. Schmidtko A, Lotsch J, et al. Ziconotide for treatment of severe chronicpain. Lancet 2010;375(9725):1569–77.35. Jackson TP, Gaeta R. Neurolytic blocks revisited. Curr Pain HeadacheRep 2008;12(1):7–13.

More magazines by this user
Similar magazines